论文部分内容阅读
目的研究化疗后骨肉瘤组织中残存肿瘤细胞MTA 1、VEGF的表达存骨肉瘤发生、发展中的作用及其与预后的相关性。方法应用免疫组化技术检测36例化疗后骨肉瘤组织残存肿瘤细胞中MTAl、VEGF的表达,应用统计学方法分析二者与预后的关系。结果化疗后残仔肿瘤细胞MTAl、VEGF的阳性表达率分别为55.56%(20/36)、44.44%(16/36),统计学分析显示与患者的预后有相关性,二者联合表达的患者预后更差。结论化疗后骨肉瘤中残存肿瘤细胞MTAl、VEGF阳性表达的患者预后差,同时检测有助于评价患者预后。
Objective To study the expression of MTA 1 and VEGF in the residual tumor cells of osteosarcoma after chemotherapy and its role in the development of osteosarcoma and its relationship with prognosis. Methods Immunohistochemical technique was used to detect the expression of MTA1 and VEGF in the residual tumor cells of 36 patients with osteosarcoma after chemotherapy. The relationship between them and prognosis was analyzed by statistical methods. Results After chemotherapy, the positive expression rates of MTA1 and VEGF in residual tumor cells were 55.56% (20/36) and 44.44% (16/36), respectively. The statistical analysis showed that the expression of MTA1 and VEGF was correlated with the prognosis of patients. The prognosis is worse. Conclusion The prognosis of patients with osteosarcoma survivin MTAl and VEGF positive expression of poor prognosis, while the test will help evaluate the prognosis of patients.